Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
De Maat
Michiel De Maat, Rotterdam NL
| Patent application number | Description | Published |
|---|---|---|
| 20090061441 | EPIGENETIC SILENCING OF CYCLOOXYGENASE-2 AFFECTS CLINICAL OUTCOME IN GASTRIC CANCER - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 03-05-2009 |
| 20100304376 | Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 12-02-2010 |
Michiel F.g. De Maat, Santa Monica, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100003689 | Use of Methylation Status of MINT Loci as a Marker for Rectal Cancer - The invention relates to methods for predicting the outcome of rectal cancer and stratifying a rectal cancer treatment according to the level of DNA methylation at MINT 1, 3, 12, or 17. Also disclosed is a method of detecting rectal adenoma or malignancy based on the level of DNA methylation at MINT 2, 3, or 31. | 01-07-2010 |
Monica Petronella Maria De Maat, Rotterdam NL
| Patent application number | Description | Published |
|---|---|---|
| 20110071083 | Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells - A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and/or LMW′) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW′ fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations. | 03-24-2011 |